Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI‐H Tumors and Immune Checkpoint Inhibitors

Since only a minority of patients with NSCLC benefit from ICIs, it is essential and prudent to continue identifying prognostic markers, such as MSI-H/dMMR and other genomic or immune signatures.

Authors

Institutions

Publication Details

Journal
Health Science Reports
Published
2026-02-01
DOI
https://doi.org/10.1002/hsr2.71838
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI‐H Tumors and Immune Checkpoint Inhibitors

Md Mohiuddin
Health Science Reports
Cancer Immunotherapy and Biomarkers
article

Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI‐H Tumors and Immune Checkpoint Inhibitors

Md Mohiuddin
article en

Abstract

Since only a minority of patients with NSCLC benefit from ICIs, it is essential and prudent to continue identifying prognostic markers, such as MSI-H/dMMR and other genomic or immune signatures.

Health Science ReportsVol. 9(2)
Southeast University (BD)
Good health and well-being
Openalex Percentile: Top 50%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI‐H Tumors and Immune Checkpoint Inhibitors — Md Mohiuddin · Health Science Reports (2026) | TGRS Research Map | TGRS